GCG and type 2 diabetes mellitus: Besides GLP-1 receptor agonists (A-GLP1), on the market since 2005, newer multi-agonist drugs that use one molecule to activate multiple receptors are drawing attention, like tirzepatide (that stimulates both the GLP-1 and the GIP receptor), currently approved for T2DM.